Cite
HARVARD Citation
Kiyota, N. et al. (2017). A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. Oral oncology. pp. 138-146. [Online].